Legal Representation
Attorney
Paul C. Llewellyn
USPTO Deadlines
Next Deadline
3440 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2014-12-16)
Due Date
December 16, 2034
Grace Period Ends
June 16, 2035
Application History
38 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 15, 2025 | 89AG | O | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | Loading... |
| May 15, 2025 | NA89 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | Loading... |
| May 15, 2025 | RNL1 | Q | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | Loading... |
| May 15, 2025 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Dec 12, 2024 | E89R | I | TEAS SECTION 8 & 9 RECEIVED | Loading... |
| Dec 16, 2023 | REM2 | E | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | Loading... |
| Jun 22, 2021 | NA15 | E | SEC. 15 ACKNOWLEDGEMENT - E-MAILED | Loading... |
| Jun 22, 2021 | NAS8 | E | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | Loading... |
| Jun 22, 2021 | 8.OK | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED | Loading... |
| Jun 22, 2021 | 15AK | O | REGISTERED - SEC. 15 ACKNOWLEDGED | Loading... |
| Jun 22, 2021 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Dec 15, 2020 | E15R | I | TEAS SECTION 15 RECEIVED | Loading... |
| Dec 15, 2020 | ES8R | I | TEAS SECTION 8 RECEIVED | Loading... |
| Dec 16, 2019 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Mar 18, 2015 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Mar 18, 2015 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Dec 16, 2014 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Nov 14, 2014 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Nov 13, 2014 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Nov 5, 2014 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 4, 2014 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 4, 2014 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Nov 4, 2014 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Oct 15, 2014 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Oct 15, 2014 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 15, 2014 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Oct 15, 2014 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 15, 2014 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 18, 2014 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 18, 2014 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 29, 2014 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 11, 2014 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Jan 10, 2014 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jan 7, 2014 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 6, 2014 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 4, 2013 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Dec 3, 2013 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 21, 2013 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
chemical compounds and additives for use in pharmaceutical research or the manufacture of pharmaceuticals
First Use Anywhere:
Jul 12, 2012
First Use in Commerce:
Oct 15, 2014
Class 005
pharmaceuticals and pharmaceutical products for treating muscular dystrophy, (( infectious diseases and viruses that respond to ribonucleic acid (RNA)-based therapies; )) pharmaceuticals comprising drugs based on Phosphorodiamidate Morpholino Oligomers technology platform, and drugs that modulate RNA expression
First Use Anywhere:
Jul 12, 2012
First Use in Commerce:
Oct 15, 2014
Class 042
medical and scientific research services, namely, medical research; medical and scientific research services all in the field of muscular dystrophy, infectious diseases and viruses that respond to ribonucleic acid (RNA) modulation therapies
First Use Anywhere:
Jul 12, 2012
First Use in Commerce:
Oct 15, 2014
Additional Information
Design Mark
The mark consists of an abstract representation of the DNA double helix structure.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
001
005
042